Detalles de la búsqueda
1.
Spatial predictors of immunotherapy response in triple-negative breast cancer.
Nature
; 621(7980): 868-876, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37674077
2.
Single Institution trial of anthracycline- and taxane-based chemotherapy for operable breast cancer: The ASTER study.
Breast J
; 25(2): 237-242, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30810258
3.
Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study.
Lancet Oncol
; 19(2): 249-256, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29326029
4.
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer.
Breast Cancer Res
; 19(1): 16, 2017 02 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-28183321
5.
Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trials.
Haematologica
; 102(10): 1748-1757, 2017 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28912173
6.
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
Lancet Oncol
; 17(6): 791-800, 2016 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-27179402
7.
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.
Lancet
; 384(9938): 164-72, 2014 Jul 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-24529560
8.
Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.
Lancet Oncol
; 15(6): 640-7, 2014 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-24657003
9.
ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.
N Engl J Med
; 365(3): 203-12, 2011 Jul 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-21774708
10.
Bortezomib plus dexamethasone followed by escalating donor lymphocyte infusions for patients with multiple myeloma relapsing or progressing after allogeneic stem cell transplantation.
Biol Blood Marrow Transplant
; 19(3): 424-8, 2013 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-23142330
11.
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
Lancet Oncol
; 13(1): 25-32, 2012 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-22153890
12.
Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth Factor Receptor 2 Therapy.
J Clin Oncol
; 41(16): 2988-2997, 2023 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36977286
13.
Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.
J Clin Oncol
; 41(16): 2998-3008, 2023 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37075276
14.
Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial.
J Clin Oncol
; 41(33): 5118-5130, 2023 Nov 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-37556775
15.
Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II).
Breast Cancer Res Treat
; 132(3): 843-51, 2012 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-21750964
16.
Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled Analysis.
Cancers (Basel)
; 14(20)2022 Oct 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-36291835
17.
Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer.
NPJ Breast Cancer
; 8(1): 1, 2022 Jan 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35013314
18.
The TRAR gene classifier to predict response to neoadjuvant therapy in HER2-positive and ER-positive breast cancer patients: an explorative analysis from the NeoSphere trial.
Mol Oncol
; 16(12): 2355-2366, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-34816585
19.
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
Lancet
; 375(9712): 377-84, 2010 Jan 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-20113825
20.
Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer.
Front Oncol
; 11: 827625, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-35223459